David A. Weber, Ph.D.
Chief Executive Officer, President and Board Member
Dr. Weber has served as Otonomy’s president and chief executive officer and on our board of directors since November 2010. Prior to joining the company, he served from February 2004 to April 2010 as the chief executive officer of MacuSight, Inc., a developer of a sustained-delivery formulation of sirolimus for the treatment of severe ophthalmic diseases. Prior to MacuSight, Dr. Weber served as acting chief executive officer and executive vice president of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003. Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber received his doctorate in medical microbiology from Creighton University and his master’s degree and bachelor’s degree in biological sciences from Wichita State University.
Paul E. Cayer
Chief Financial and Business Officer
Mr. Cayer has served as Otonomy’s chief business officer since October 2008, chief financial officer since October 2010, and secretary since February 2011. He brings more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Prior to joining our company, Mr. Cayer served from 2005 to 2008 as senior vice president, corporate development for Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. From 2001 to 2005, Mr. Cayer served as the chief financial officer and senior vice president, business development of Targeted Molecules Corporation, a biopharmaceutical company. Mr. Cayer has also held various management positions with Gensia Pharmaceuticals, Inc., a biopharmaceutical company, Acuson, a provider of medical ultrasound systems, Castle & Cooke, a consumer products company and served as consultant with Booz-Allen & Hamilton, a management and technology consulting firm. Mr. Cayer received his master’s degree in business and bachelor’s degree in biomechanical engineering from Harvard University.
Carl LeBel, Ph.D.
Chief Scientific Officer
Dr. LeBel has served as Otonomy’s chief scientific officer since April 2009. Dr. LeBel has more than 25 years of pharmaceutical research and development experience. From 2003 to 2007, Dr. LeBel served as executive director and from 1993 to 2003 in a variety of other positions, at Amgen, Inc., a biopharmaceutical company. From 1991 to 1993, Dr. LeBel served as research scientist at Alkermes, Inc., a biopharmaceutical company. From 1990 to 1991, Dr. LeBel served as a consultant at Arthur D. Little, Inc., a management and technology consulting firm. He is also a scientific fellow of the American Academy of Otolaryngology—Head & Neck Surgery, a full member of the Association for Research in Otolaryngology and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel received a doctorate in biomedical sciences/toxicology from Northeastern University and a bachelor’s degree in chemistry from the University of Detroit.
Robert Michael Savel, II
Chief Technical Officer
Mr. Savel has served as Otonomy’s chief technical officer since January 2014. From 2011 to December 2013, Mr. Savel served as general manager and senior vice president of operations for Optimer Pharmaceuticals, Inc., a biopharmaceutical company. From 2010 to 2011, Mr. Savel served as senior vice president and chief technical officer for Inspire Pharmaceuticals, Inc., an ophthalmic pharmaceutical company. From 2008 to 2010, Mr. Savel served as president of Savel Enterprises LLC, a management consulting firm. From 2007 to 2008, Mr. Savel served as the senior vice president of Technical Operations for PDL BioPharma, an antibody manufacturer. Earlier in his career, he held leadership operating positions with Johnson & Johnson, a medical devices, pharmaceutical and consumer packaged goods manufacturer, which included the position of vice president, Quality and Compliance. Mr. Savel received his bachelor’s degree in mechanical engineering from Virginia Polytechnic Institute and State University.
Anthony J. Yost
Chief Commercial Officer
Tony Yost has served as Otonomy’s chief commercial officer since October 2014. Mr. Yost has a strong track record in developing and implementing successful commercialization strategies in the life science industry including repeat experience in building and managing sales and marketing teams, and launching more than 20 new products. He joins Otonomy after serving as chief commercial officer for specialty pharmaceutical companies Prometheus Laboratories and EKR Therapeutics. Previously he served as general manager for the Western U.S. Operating Unit of Novartis Pharmaceuticals where he led commercial operations totaling more than 600 employees generating annual revenues in excess of $600 million. Mr. Yost joined Novartis after serving as president of Innovex, the U.S.-based pharmaceutical sales and marketing services division of Quintiles Transnational. At Innovex, he was responsible for more than 2,000 employees providing commercial services for both large and small pharmaceutical clients across a broad range of therapeutic areas. Mr. Yost has also held various commercial and general management positions at Schering-Plough, Boehringer Mannheim Pharmaceuticals and Eli Lilly and Company. He received a Bachelor of Science in Pharmacy from Purdue University.